"Do not be mistaken, inevitably there will be another epidemic of flu – this may happen next year, or in the next 15 years, but it is inevitable and we can not prevent it," he added. "There is a tremendous value in the accumulation and maintenance of antibiotics, so we are ready."
T A study published in the journal Health Economics created a mathematical basis for assessing the cost of the illness, based on assumptions about the UK's preparedness plan.
He urges governments to create stocks of both new and existing antibiotics for the worst scenarios. Savings from inventory of drugs ready for deployment immediately result from economic costs for a high death rate, avoidance of treatment and loss of working days.
"Our model captures the economic benefits of maintaining antibiotics," said Itarar Megiddo, a research fellow at the University of Strathclyde. "It's important to understand how much we have to pay for antibiotics that we do not use immediately."
Prof. "If such a structure were to exist, it would act as a mechanism that would stimulate innovation from drug companies," he said. "Antibiotic resistance is a problem on a daily basis, but in fact, during a pandemic influenza, we will see the real scale of the problem. We have to prepare."